---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-035449"
form_type: "8-K"
ticker: null
cik: "0000922247"
company_name: "Cyclo Therapeutics, Inc."
filed_at: "2023-12-28T23:59:59+00:00"
generated_at: "2026-06-07T06:42:22.714663+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cyclo Therapeutics completes all-stock merger with Applied Molecular Transport; issues ~5.8M shares

## Summary
- Merger closed; AMTI stockholders receive 0.1331 CYTH shares per AMTI share.
- Cyclo issued ~5.82M shares to AMTI holders, representing ~18% of combined fully diluted company.
- Combined co continues as Cyclo Therapeutics (CYTH); primary focus on Phase 3 Trappsol Cyclo for NPC1.
- Pro forma cash ~$11.0M; expected operating runway into 2H 2024.
- Shawn Cross, former AMTI CEO, appointed to Cyclo board as independent director.

## SEC filing metadata
- accession: 0001437749-23-035449
- form_type: 8-K
- cik: 0000922247
- company_name: Cyclo Therapeutics, Inc.
- filed_at: 2023-12-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/922247/000143774923035449/0001437749-23-035449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/922247/000143774923035449/ctdh20231227_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-035449
- JSON: https://secwatch.observer/filing/0001437749-23-035449.json
- Plain text: https://secwatch.observer/filing/0001437749-23-035449.txt

## Key facts
- Executive change
  Shawn Cross was appointed as Director at Cyclo Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On December 27, 2023, effective as of the Effective Time, Shawn Cross, a former director and former Chief Executive Officer of AMTI, was appointed to the Board to serve as a member of the Board, until his successor has been duly elected and qualified, or until his earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/922247/000143774923035449/0001437749-23-035449-index.htm
- M&A Transactions
  Cyclo Therapeutics, Inc. underwent a change of control involving Applied Molecular Transport Inc. for 0.1331 shares of Cyclo Common Stock per share of AMTI Common Stock (closed 2023-12-27).
  - Action: change of control
  - Counterparty: Applied Molecular Transport Inc.
  - Consideration: 0.1331 shares of Cyclo Common Stock per share of AMTI Common Stock
  - Closing: 2023-12-27
  source text: Stock held directly by Cyclo or Merger Sub) was automatically converted into the right to receive a number of shares of common stock of Cyclo (“Cyclo Common Stock”) equal to 0.1331 (the “Exchange Ratio”). No fractional shares of Cyclo Common Stock were issued in connection with the Merger and the number of shares of Cyclo Common Stock issued to the AMTI
  evidence_url: https://www.sec.gov/Archives/edgar/data/922247/000143774923035449/0001437749-23-035449-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.